Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

SPDR® S&P Biotech ETF (XBI)

Delayed Data
As of May 02
 +1.07 / +1.98%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

No recent news for SPDR® S&P Biotech ETF.


1 month+6.86% 3 years+15.67%
3 months+6.91% 5 years+17.53%
1 year-24.62% Since inception+12.67%
Data through 04/30/2016

Quote Details

Previous close$53.93
Open day’s range53.19 – 55.05
Net asset value (NAV)53.92 (04/29/2016)
Daily volume4,682,267
Average volume (3 months)7,370,529
Data as of 3:59pm ET, 05/02/2016

Peer Comparisonvs. Health ETFs

Performance 5-yr return+17.53%+15.78%
Expense Gross exp ratio0.35%0.47%
Risk 5 year sharpe ratio0.731.00
Net assets$1.9B$1.2B
Average market cap$3.4B$28.1B
Average P/E--22.4
Dividend / Share--0.22%


XLV Health Care Select Sector SPDR® Fund
VHT Vanguard Health Care Index Fund ETF Shar...
RYH Guggenheim S&P 500® Equal Weight Health...


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ACAD ACADIA Pharmaceuticals Inc2.68%
MDVN Medivation Inc2.28%
NBIX Neurocrine Biosciences Inc2.16%
ICPT Intercept Pharmaceuticals Inc2.12%
NVAX Novavax Inc2.05%
SGEN Seattle Genetics Inc2.04%
RARE Ultragenyx Pharmaceutical Inc2.04%
LGND Ligand Pharmaceuticals Inc2.04%
ALKS Alkermes Plc2.01%
AMGN Amgen2.01%

Partner Offers